Bridging the Gap to Care: What You Need to Know About ATTR-CM Amyloidosis

Published: Sept. 13, 2023, 4 a.m.

Guest: Mazen Hanna, MD
\n\n Guest: Marianna Fontana, MD
\n\n\n \n

Once thought to be a rare disease, transthyretin amyloidosis that results in cardiomyopathy (ATTR-CM) remains a challenge to diagnose and treat. In this discussion, Drs. Mazen Hanna and Marianna Fontana provide expert advice on imaging techniques to diagnose ATTR-CM, including recognizing diagnostic \u201cred flags.\u201d They also review recent clinical trial data of current and potential therapeutics for ATTR-CM, so listen in to find out how you can put the evidence into practice.